diflorasone diacetate

diflorasone diacetate

[dīflôr′əsōn dī·as′ətāt]
a topical corticosteroid with high potency.
indication It is prescribed for the treatment of skin inflammation.
contraindications Viral and fungal diseases of the skin, impaired circulation, or known hypersensitivity to this drug or to other steroidal medication prohibits its use.
adverse effects Among the more serious adverse reactions, usually occurring after prolonged or excessive application, are striae, hypopigmentation, local irritation of the skin, and various systemic effects.

diflorasone diacetate

(dif´lorəsōn dīas´ətāt),
n brand names: Florone, Maxiflor, Psorcon;
drug class: topical corticosteroid, group II high potency;
action: possesses antipruritic, antiinflammatory actions;
uses: psoriasis, eczema, contact dermatitis, pruritus.

diflorasone diacetate

a corticosteroid used topically in treatment of inflammatory skin diseases.
References in periodicals archive ?
TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis: effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines.
Over the next 5 to 6 months, her discomfort precipitated 5 visits to her primary care physician, who treated her with diflorasone diacetate ointment 0.
Food and Drug Administration (FDA) approving its Abbreviated New Drug Application (ANDA) for Diflorasone Diacetate Cream USP, 0.
Taro's Diflorasone Diacetate Cream is a high-potency topical corticosteroid indicated for the treatment of moderate to severe dermatologic conditions.
Taro's May 1999 approval for Diflorasone Diacetate Ointment USP, 0.
The topical products were Diflorasone Diacetate Cream, bioequivalent to Dermik Laboratories' Psorcon(R) Cream, with a U.
Taro also received ANDA approval for Diflorasone Diacetate Cream, all three strengths of Clorazepate Dipotassium Tablets, all four strengths of Nortriptyline Hydrochloride Capsules, and Clobetasol Emollient Cream, as well as a supplemental ANDA approval for an additional strength of Etodolac Tablets.
During the second quarter of 2000, Taro received FDA approval for its New Drug Application for Clotrimazole 3-Day Vaginal Cream, its ANDAs for Diflorasone Diacetate Cream, Clorazepate Dipotassium Tablets, Nortriptyline Hydrochloride Capsules, and Clobetasol E Cream, as well as a supplemental ANDA approval for an additional strength of Etodolac Tablets.
Earlier this quarter, Taro's NDA for Clotrimazole Three-Day Cream 2% was approved, as well as ANDAs for Diflorasone Diacetate Cream, Clorazepate Dipotassium Tablets and a supplemental ANDA approval for Etodolac Tablets, 500mg.
In April, Taro received FDA approval for its NDA for Clotrimazole 3-Day Vaginal Cream, its ANDAs for Diflorasone Diacetate Cream and Clorazepate Dipotassium Tablets, and a supplemental ANDA approval for an additional strength of Etodolac Tablets.
Three of these approvals were for high-potency topical corticosteroid products indicated for the treatment of moderate to severe dermatologic conditions: Diflorasone Diacetate Ointment, 0.
Taro's Diflorasone Diacetate Ointment, is a high-potency topical corticosteroid indicated for the treatment of moderate to severe dermato Dermik Laboratories' Psorcon(R).